应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00719 山东新华制药股份
休市中 05-02 11:25:14
5.490
+0.000
0.00%
最高
5.490
最低
5.490
成交量
0.00
今开
5.490
昨收
5.490
日振幅
0.00%
总市值
37.88亿
流通市值
10.71亿
总股本
6.90亿
成交额
0.00
换手率
0.00%
流通股本
1.95亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
智通AH统计|4月29日
智通财经 · 04-29
智通AH统计|4月29日
图解新华制药一季报:第一季度单季净利润同比减20.99%
证券之星 · 04-28
图解新华制药一季报:第一季度单季净利润同比减20.99%
山东新华制药股份(00719):阿司匹林肠溶片新增规格及通过仿制药一致性评价
智通财经 · 04-28
山东新华制药股份(00719):阿司匹林肠溶片新增规格及通过仿制药一致性评价
山东新华制药股份(00719)收到国家药监局核准签发的甲钴胺片《药品补充申请批准通知书》
智通财经 · 04-28
山东新华制药股份(00719)收到国家药监局核准签发的甲钴胺片《药品补充申请批准通知书》
山东新华制药股份(00719)第一季净利润同比下滑20.99%
金吾财讯 · 04-28
山东新华制药股份(00719)第一季净利润同比下滑20.99%
山东新华制药股份(00719)一季度归母净利润1.12亿元,同比下降20.99%
智通财经 · 04-28
山东新华制药股份(00719)一季度归母净利润1.12亿元,同比下降20.99%
新华制药:公司无应披露而未披露重大信息
证券之星 · 04-25
新华制药:公司无应披露而未披露重大信息
山东新华制药股份取得普瑞巴林口服溶液药品注册证书
智通财经 · 04-23
山东新华制药股份取得普瑞巴林口服溶液药品注册证书
山东新华制药股份(00719)取得普瑞巴林口服溶液药品注册证书
智通财经 · 04-23
山东新华制药股份(00719)取得普瑞巴林口服溶液药品注册证书
山东新华制药股份(00719)取得盐酸美金刚口服溶液药品注册证书
智通财经 · 04-23
山东新华制药股份(00719)取得盐酸美金刚口服溶液药品注册证书
智通AH统计|4月23日
智通财经 · 04-23
智通AH统计|4月23日
山东新华制药股份(00719)收到国家药品监督管理局核准签发的艾司唑仑片(1mg、2mg)《药品补充申请批准通知书》
智通财经 · 04-14
山东新华制药股份(00719)收到国家药品监督管理局核准签发的艾司唑仑片(1mg、2mg)《药品补充申请批准通知书》
山东新华制药股份(00719)氨茶碱片通过药监局仿制药质量和疗效一致性评价
金吾财讯 · 04-14
山东新华制药股份(00719)氨茶碱片通过药监局仿制药质量和疗效一致性评价
山东新华制药股份(00719):氨茶碱片通过仿制药一致性评价
智通财经 · 04-14
山东新华制药股份(00719):氨茶碱片通过仿制药一致性评价
新华制药3709.2万股限售股将于4月14日解禁,占总股本5.38%
证券之星 · 04-14
新华制药3709.2万股限售股将于4月14日解禁,占总股本5.38%
山东新华制药股份03月05日主力净流入61万元 散户资金抛售
市场透视 · 03-05
山东新华制药股份03月05日主力净流入61万元 散户资金抛售
新华制药获批成为“硫酸氢氯吡格雷片 ”上市许可持有人
智通财经 · 03-03
新华制药获批成为“硫酸氢氯吡格雷片 ”上市许可持有人
山东新华制药股份(00719)收到硫酸氢氯吡格雷片《药品补充申请批准通知书》
智通财经 · 03-03
山东新华制药股份(00719)收到硫酸氢氯吡格雷片《药品补充申请批准通知书》
新华制药:感谢您对公司关注与支持,感谢您的意见与建议
证星董秘互动 · 02-20
新华制药:感谢您对公司关注与支持,感谢您的意见与建议
新华制药:公司始终坚持走源头减排工程治理之路
互动易 · 02-10
新华制药:公司始终坚持走源头减排工程治理之路
加载失败,点击重试
公司概况
公司名称:
山东新华制药股份
所属市场:
SEHK
上市日期:
--
主营业务:
山东新华制药股份有限公司是一家主要从事化学原料药、制剂和医药中间体的开发、制造和销售的中国公司。该公司的产品主要包括安乃近、咖啡因、氨基比林、阿斯匹林、氢化可的松、吡哌酸、布洛芬、左旋多巴、吡哌酸片、复方甘草片和尼莫地平片等。该公司的产品销往中国国内与海外市场,包括美洲和欧洲等。
发行价格:
--
{"stockData":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":5.49,"timestamp":1746156314113,"preClose":5.49,"halted":0,"volume":0,"delay":0,"floatShares":195000000,"shares":690000000,"eps":0.740546257060264,"marketStatus":"休市中","change":0,"latestTime":"05-02 11:25:14","open":5.49,"high":5.49,"low":5.49,"amount":0,"amplitude":0,"askPrice":5.54,"askSize":4000,"bidPrice":5.51,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":0.7307965568928637,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":7,"adr":0,"listingDate":851961600000,"exchange":"SEHK","adjPreClose":5.49,"dividendRate":0.053338,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":13.68,"timestamp":1745996400000,"preClose":13.76,"halted":0,"volume":6175000,"delay":0,"premium":"-62.66"}},"requestUrl":"/m/hq/s/00719/tweets","defaultTab":"tweets","newsList":[{"id":"2531273704","title":"智通AH统计|4月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2531273704","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531273704?lang=zh_cn&edition=full","pubTime":"2025-04-29 16:15","pubTimestamp":1745914506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,截止4月29日收盘,东北电气、安德利果汁、弘业期货分列AH溢价率前三位,溢价率分别为958.82%、336.85%、320.09%;招商银行、比亚迪股份、药明康德分列AH溢价率末三位,溢价率分别为13.06%、15.59%、19.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1813983027.USD","00553","LU0640798160.USD","00338","06869","00670","03968","002594","00568","IE0008368742.USD","LU0516422440.USD","03606","01349","BK1205","IE00BMCWC346.EUR","81211","01658","01330","BYDDY","IE0031814852.USD","01211","01057","01812","02218","00323","03143","LU1303224171.USD","02238","02866","159982","00300","00719","03678","00956","01108","01033","01877","01787","HYDD.SI","02208","02899","00042","399300","02338","BK1540","00347","01988","02359"],"gpt_icon":1},{"id":"2531526342","title":"图解新华制药一季报:第一季度单季净利润同比减20.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531526342","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531526342?lang=zh_cn&edition=full","pubTime":"2025-04-29 04:22","pubTimestamp":1745871740,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药2025年一季报显示,公司主营收入24.3亿元,同比下降1.81%;归母净利润1.12亿元,同比下降20.99%;扣非净利润1.05亿元,同比下降23.74%;负债率41.86%,投资收益-76.02万元,财务费用403.52万元,毛利率18.75%。财报数据概要请见下图:","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429042456a46aeff9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429042456a46aeff9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00719"],"gpt_icon":0},{"id":"2530263594","title":"山东新华制药股份(00719):阿司匹林肠溶片新增规格及通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2530263594","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530263594?lang=zh_cn&edition=full","pubTime":"2025-04-28 16:55","pubTimestamp":1745830555,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,近日,公司收到国家药品监督管理局核准签发的阿司匹林肠溶片(100mg)的《药品补充申请批准通知书》,本品通过仿制药质量和疗效一致性评价。阿司匹林肠溶片为血液系统用药,临床上主要用于不稳定性心绞痛(标准治疗的一部分);急性心肌梗死(标准治疗的一部分);预防心肌梗死复发;动脉血管手术或介入手术后,如主动脉冠状动脉静脉搭桥术、经皮冠状动脉腔内血管成形术;预防短暂性脑缺血发作(TIA)和已出现早期症状后预防脑梗死。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00719","BK1515"],"gpt_icon":0},{"id":"2530385426","title":"山东新华制药股份(00719)收到国家药监局核准签发的甲钴胺片《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2530385426","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530385426?lang=zh_cn&edition=full","pubTime":"2025-04-28 16:55","pubTimestamp":1745830502,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,近日,该公司收到国家药品监督管理局核准签发的甲钴胺片(以下简称“本品”)《药品补充申请批准通知书》,批准本品上市许可持有人转让补充申请。公告称,甲钴胺片于2025年4月通过国家药品监督管理局审批,新华制药成为本品的上市许可持有人。该产品的上市,有利于丰富公司神经系统药物产品线,提升公司综合竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"山东新华制药股份(00719)收到国家药监局核准签发的甲钴胺片《药品补充申请批准通知书》","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00719","BK1515","BK1191"],"gpt_icon":0},{"id":"2530269374","title":"山东新华制药股份(00719)第一季净利润同比下滑20.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530269374","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530269374?lang=zh_cn&edition=full","pubTime":"2025-04-28 16:52","pubTimestamp":1745830368,"startTime":"0","endTime":"0","summary":"金吾财讯 | 山东新华制药股份(00719)公布2025年第一季度未经审核的业绩。期内,归属于上市公司股东的净利润1.12亿元(人民币,下同),同比下滑20.99%;基本每股收益0.15元,去年同期为0.21元。期内,集团营业收入24.3亿元,同比减少1.81%。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZDU3MjExMzhjMmFmNDFjMDg5MzczN2Y3MTNmMTc0NDI4NjU0MjU0ODcxMjc5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDU3MjExMzhjMmFmNDFjMDg5MzczN2Y3MTNmMTc0NDI4NjU0MjU0ODcxMjc5.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957831","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719"],"gpt_icon":0},{"id":"2530425709","title":"山东新华制药股份(00719)一季度归母净利润1.12亿元,同比下降20.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530425709","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530425709?lang=zh_cn&edition=full","pubTime":"2025-04-28 16:48","pubTimestamp":1745830088,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布2025年第一季度业绩,营业收入24.3亿元(人民币,下同),同比下降1.81%;归属于上市公司股东的净利润1.12亿元,同比下降20.99%;基本每股收益0.15元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00719"],"gpt_icon":0},{"id":"2530609970","title":"新华制药:公司无应披露而未披露重大信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2530609970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530609970?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:31","pubTimestamp":1745569879,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药(000756)04月25日在投资者关系平台上答复投资者关心的问题。投资者:尊敬的董秘,您好!请问贵公司最近有没有资产重组计划在进行,公司效益前景如何?新华制药董秘:您好!公司将于4月29日发布季度报告。除此之外,截至目前,公司无应披露而未披露重大信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425163522a6c7c430&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425163522a6c7c430&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","00719"],"gpt_icon":0},{"id":"2529783485","title":"山东新华制药股份取得普瑞巴林口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2529783485","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529783485?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:57","pubTimestamp":1745398620,"startTime":"0","endTime":"0","summary":"山东新华制药股份发布公告,近日,该公司收到国家药品监督管理局核准签发...山东新华制药股份发布公告,近日,该公司收到国家药品监督管理局核准签发的普瑞巴林口服溶液《药品注册证书》。新华制药的普瑞巴林口服溶液于2025年4月取得药品注册证书,该产品的获批上市将进一步丰富公司产品结构,提高市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423170146a6c4ef28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423170146a6c4ef28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00719","BK1191","BK1515"],"gpt_icon":0},{"id":"2529836524","title":"山东新华制药股份(00719)取得普瑞巴林口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2529836524","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529836524?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:41","pubTimestamp":1745397669,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,近日,该公司收到国家药品监督管理局核准签发的普瑞巴林口服溶液(以下简称“本品”)《药品注册证书》。普瑞巴林用于带状疱疹后神经痛、纤维肌痛、成人部分性癫痫发作的添加治疗。普瑞巴林口服溶液是《国家基本医疗保险、工伤保险和生育保险药品目录》(2024年版)乙类品种,根据有关统计数据显示,2023年中国公立医疗机构普瑞巴林制剂销售额约为人民币6.24亿元。新华制药的普瑞巴林口服溶液于2025年4月取得药品注册证书,该产品的获批上市将进一步丰富公司产品结构,提高市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"山东新华制药股份(00719)取得普瑞巴林口服溶液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00719","BK1515"],"gpt_icon":0},{"id":"2529363521","title":"山东新华制药股份(00719)取得盐酸美金刚口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2529363521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529363521?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:39","pubTimestamp":1745397549,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,近日,山东新华制药股份有限公司(以下简称“新华制药”或“本公司”)收到国家药品监督管理局核准签发的盐酸美金刚口服溶液(以下简称“本品”)《药品注册证书》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00719","BK1191","BK1515"],"gpt_icon":0},{"id":"2529526888","title":"智通AH统计|4月23日","url":"https://stock-news.laohu8.com/highlight/detail?id=2529526888","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529526888?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:15","pubTimestamp":1745396105,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,截止4月23日收盘,东北电气、弘业期货、安德利果汁分列AH溢价率前三位,溢价率分别为938.46%、330.54%、327.65%;招商银行、比亚迪股份、药明康德分列AH溢价率末三位,溢价率分别为13.93%、14.13%、17.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00347","02359","LU0384037296.USD","02218","LU0502904849.HKD","02465","002594","00956","01658","00187","02866","BK1610","BYDDY","06066","00553","00300","01988","00568","HYDD.SI","159982","399300","01812","00719","00914","02068","81211","06869","00317","06690","LU2249611893.SGD","00991","601633","03968","03678","00042","82333","02338","03143","01211","01330","01877","01108","01349","03369","01057","GWLLY","02333","01033","03606"],"gpt_icon":1},{"id":"2527618381","title":"山东新华制药股份(00719)收到国家药品监督管理局核准签发的艾司唑仑片(1mg、2mg)《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2527618381","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527618381?lang=zh_cn&edition=full","pubTime":"2025-04-14 16:53","pubTimestamp":1744620829,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,近日,该公司收到国家药品监督管理局核准签发的艾司唑仑片(1mg、2mg)(以下简称“本品”)《药品补充申请批准通知书》,批准本品上市许可持有人转让补充申请。艾司唑仑片(1mg、2mg)于2025年4月通过国家药品监督管理局审批,新华制药成为本品的上市许可持有人。该产品的上市,有利于丰富公司精麻药品系列产品线,提升公司综合竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"山东新华制药股份(00719)收到国家药品监督管理局核准签发的艾司唑仑片(1mg、2mg)《药品补充申请批准通知书》","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","00719"],"gpt_icon":0},{"id":"2527186477","title":"山东新华制药股份(00719)氨茶碱片通过药监局仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2527186477","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527186477?lang=zh_cn&edition=full","pubTime":"2025-04-14 16:49","pubTimestamp":1744620577,"startTime":"0","endTime":"0","summary":"金吾财讯 | 山东新华制药股份(00719)公布,公司收到国家药品监督管理局核准签发的氨茶碱片(《药品补充申请批准通知书》,该产品通过仿制药质量和疗效一致性评价。本品对呼吸道平滑肌有直接松弛作用,适用于支气管哮喘、喘息型支气管炎、阻塞性肺气肿等缓解喘息症状;也可用于心源性肺水肿引起的哮喘。氨茶碱片属于《国家基本药物目录》与《国家基本医疗保险、工伤保险和生育保险药品目录(2023年)》甲类品种,根据有关统计数据显示,2023年中国公立医疗机构氨茶碱销售额约为人民币6.51亿元。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/MTczNjE1NTkxMzE1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/MTczNjE1NTkxMzE1OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957172","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00719","BK1515"],"gpt_icon":0},{"id":"2527907229","title":"山东新华制药股份(00719):氨茶碱片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2527907229","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527907229?lang=zh_cn&edition=full","pubTime":"2025-04-14 16:32","pubTimestamp":1744619579,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,近日,山东新华制药股份有限公司(以下简称“新华制药”或“本公司”)收到国家药品监督管理局核准签发的氨茶碱片(以下简称“本品”)《药品补充申请批准通知书》,该产品通过仿制药质量和疗效一致性评价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00719","BK1191","BK1515"],"gpt_icon":0},{"id":"2527911729","title":"新华制药3709.2万股限售股将于4月14日解禁,占总股本5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527911729","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527911729?lang=zh_cn&edition=full","pubTime":"2025-04-14 08:09","pubTimestamp":1744589352,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,新华制药于4月14日将有3709.2万股限售股份解禁,为公司定向增发机构配售股份,占公司总股本5.38%。本次解禁后,公司还有215.26万股限售股份,占总股本0.31%。新华制药主营业务:开发、制造和销售化学原料药、制剂、医药中间体及其他产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414081542a457dc2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414081542a457dc2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00719","BK1191","BK1515"],"gpt_icon":0},{"id":"2517995807","title":"山东新华制药股份03月05日主力净流入61万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2517995807","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517995807?lang=zh_cn&edition=full","pubTime":"2025-03-05 16:16","pubTimestamp":1741162580,"startTime":"0","endTime":"0","summary":"03月05日, 山东新华制药股份股价涨0.53%,报收5.69元,成交金额818万元,换手率0.74%,振幅1.24%,量比0.62。山东新华制药股份今日主力资金净流入61万元,上一交易日主力净流出0万元。该股近5个交易日下跌2.07%,主力资金累计净流出2万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出203万元,其中净流出天数为6日。该股主力净额占比0.06%,港股市场排名165/2652。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170305a2605a7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170305a2605a7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00719","BK1515"],"gpt_icon":0},{"id":"2516500055","title":"新华制药获批成为“硫酸氢氯吡格雷片 ”上市许可持有人","url":"https://stock-news.laohu8.com/highlight/detail?id=2516500055","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516500055?lang=zh_cn&edition=full","pubTime":"2025-03-03 16:44","pubTimestamp":1740991464,"startTime":"0","endTime":"0","summary":"新华制药发布公告,近日,公司收到国家药品监督管理局核准签发的硫酸氢氯吡格雷片《药品补充申请批准通知书》,批准本品上市许可持有人转让补充申请。据悉,硫酸氢氯吡格雷片为循环系统疾病药物,系一种前体药物,其代谢产物之一是血小板聚集抑制剂。硫酸氢氯吡格雷片于2025年2月通过国家药品监督管理局审批,新华制药成为本品的上市许可持有人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303165527a25cd460&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303165527a25cd460&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","00719"],"gpt_icon":0},{"id":"2516023635","title":"山东新华制药股份(00719)收到硫酸氢氯吡格雷片《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2516023635","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516023635?lang=zh_cn&edition=full","pubTime":"2025-03-03 16:32","pubTimestamp":1740990730,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份(00719)发布公告,近日,该公司收到国家药品监督管理局核准签发的硫酸氢氯吡格雷片(以下简称“本品”)《药品补充申请批准通知书》,批准本品上市许可持有人转让补充申请。公告称,硫酸氢氯吡格雷片于2025年2月通过国家药品监督管理局审批,新华制药成为本品的上市许可持有人。该产品的上市,有利于丰富公司循环系统药物产品线,提升公司综合竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","00719"],"gpt_icon":0},{"id":"2512419341","title":"新华制药:感谢您对公司关注与支持,感谢您的意见与建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2512419341","media":"证星董秘互动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512419341?lang=zh_cn&edition=full","pubTime":"2025-02-20 17:00","pubTimestamp":1740042044,"startTime":"0","endTime":"0","summary":"证券之星消息,新华制药02月20日在投资者关系平台上答复投资者关心的问题。请问董秘,如何看待AI制药领域未来的前景,以及公司未来在AI制药领域的战略布局?业内传闻同属山东国资委旗下的新华制药和鲁抗医药正在谋划国资并购重组,请问董秘方便透露目前的最新进展吗?巨潮资讯网是公司指定的信息披露媒体,目前公司无应披露而未披露的重大信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220170331988c179b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220170331988c179b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00719","BK1191","BK1574","01477","BK1515"],"gpt_icon":0},{"id":"2510885001","title":"新华制药:公司始终坚持走源头减排工程治理之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2510885001","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510885001?lang=zh_cn&edition=full","pubTime":"2025-02-10 11:33","pubTimestamp":1739158391,"startTime":"0","endTime":"0","summary":"有投资者向新华制药提问, 尊敬的公司领导,您好!我是一名普通公民,非常关心城市的空气质量。请问在日常的生产经营过程中,贵公司是否实施了有效的措施来减少对空气的污染?美好的生活环境需要大家共同守护,希望贵公司能在这方面发挥积极作用公司回答表示,正如您所愿,美好的生活环境需要大家共同守护。公司始终坚持走源头减排、工程治理、绿色低碳、循环经济发展之路。坚持多措并举、守正创新,全面提升公司环保管理绩效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210114542a23ff103&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210114542a23ff103&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","00719"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xhzy.com","stockEarnings":[{"period":"1week","weight":-0.0249},{"period":"1month","weight":-0.0631},{"period":"3month","weight":-0.0317},{"period":"6month","weight":-0.0647},{"period":"1year","weight":0.0531},{"period":"ytd","weight":-0.0551}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":-0.0301},{"period":"3month","weight":0.1127},{"period":"6month","weight":0.0974},{"period":"1year","weight":0.236},{"period":"ytd","weight":0.1219}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东新华制药股份有限公司是一家主要从事化学原料药、制剂和医药中间体的开发、制造和销售的中国公司。该公司的产品主要包括安乃近、咖啡因、氨基比林、阿斯匹林、氢化可的松、吡哌酸、布洛芬、左旋多巴、吡哌酸片、复方甘草片和尼莫地平片等。该公司的产品销往中国国内与海外市场,包括美洲和欧洲等。","yearOnYearQuotes":[{"month":1,"riseRate":0.586207,"avgChangeRate":-0.015008},{"month":2,"riseRate":0.793103,"avgChangeRate":0.103834},{"month":3,"riseRate":0.448276,"avgChangeRate":-0.005218},{"month":4,"riseRate":0.724138,"avgChangeRate":0.105324},{"month":5,"riseRate":0.310345,"avgChangeRate":-0.003465},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.006604},{"month":7,"riseRate":0.571429,"avgChangeRate":0.006209},{"month":8,"riseRate":0.296296,"avgChangeRate":-0.041364},{"month":9,"riseRate":0.37037,"avgChangeRate":-0.017083},{"month":10,"riseRate":0.464286,"avgChangeRate":0.010896},{"month":11,"riseRate":0.535714,"avgChangeRate":0.01142},{"month":12,"riseRate":0.607143,"avgChangeRate":0.027551}],"exchange":"SEHK","name":"山东新华制药股份","nameEN":"SHANDONG XINHUA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"山东新华制药股份,00719,山东新华制药股份股票,山东新华制药股份股票老虎,山东新华制药股份股票老虎国际,山东新华制药股份行情,山东新华制药股份股票行情,山东新华制药股份股价,山东新华制药股份股市,山东新华制药股份股票价格,山东新华制药股份股票交易,山东新华制药股份股票购买,山东新华制药股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}